[2]Five-YearOverall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer TreatedWith Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Published atjco.orgon June 2, 2019. [3]Garon E B,Rizvi N A, Hui R, Leighl N,Balmanoukian AS, Eder JP, et al. Pembrolizumab for...
We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum鈥揵ased chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837).MethodsAdults with pathologically ...
[13]Boyer M, Şendur MAN, Rodríguez-Abreu D, et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. J Clin Oncol. 2021 Jan 29:JCO2003579. doi: 10.1200/J...
Clinical trial information: NCT03675737 .doi:10.1200/jco.2023.41.16_suppl.4014S. RhaL. WyrwiczP.E. Yanez WeberY. BaiM. RyuJeeyun LeeF. RiveraG. AlvesM. GarridoK. ShiuAmerican Society of Clinical OncologyJournal of Clinical Oncology